Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 2/20 | 0.67 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.67 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.67 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.62 |
| ▸ | NOTUM | Q6P988 | 16/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19211484 | 0.84 | RXRA (0.72) | RXRAGRIN1GRIN2B | |
| SCHEMBL19211455 | 0.84 | NOTUM (0.71) | RXRAGRIN1GRIN2BP2RX7NOTUM | |
| SCHEMBL19211402 | 0.83 | NOTUM (0.66) | RXRAGRIN1GRIN2BNOTUMKDM4E | |
| SCHEMBL19211430 | 0.82 | NOTUM (0.76) | RXRAGRIN1GRIN2BNOTUMKDM4E | |
| SCHEMBL19221823 | 0.80 | RXRA (1.00) | RXRAGRIN1GRIN2B | |
| SCHEMBL19211410 | 0.79 | NOTUM (0.76) | RXRAGRIN1GRIN2BNOTUMKDM4E | |
| SCHEMBL19211508 | 0.79 | NOTUM (0.70) | RXRAGRIN1GRIN2BNOTUMKDM4E | |
| SCHEMBL30930742 | 0.79 | P2RX7 (0.55) | P2RX7NOTUM | |
| SCHEMBL19211361 | 0.78 | RXRA (0.69) | RXRAGRIN1GRIN2BNOTUM | |
| SCHEMBL19211436 | 0.77 | RXRA (0.70) | RXRAGRIN1GRIN2BNOTUM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109071488-B | Substituted 1,2, 3-triazoles as NR 2B-selective NMDA modulators | 詹森药业有限公司 | 2021-08-13 | — | — | CN | disclosed |
| EP-3414233-A1 | SUBSTITUTED 1,2,3-TRIAZOLES AS NR2B-SELECTIVE NMDA MODULATORS | Janssen Pharmaceutica NV (BE) | 2018-12-19 | — | — | EP | disclosed |
| WO-2017139428-A1 | SUBSTITUTED 1,2,3-TRIAZOLES AS NR2B-SELECTIVE NMDA MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2017-08-17 | — | — | WO | disclosed |